Three studies presented today at the 22nd Annual Meeting of the Neuro-Interventional Surgery Society (SNIS) discussed whether the use of LPG-1 inhibitors could reduce the impacts of the stroke and related brain lesions or reduce the risk of complete stroke. These medications, which reduce blood sugar already cause weight loss, are commonly prescribed for diabetes and type 2 obesity and include medications such as semaglutida (Ozempic).
In the first study, “the impact of semaglutida (Ozempic) on mortality and survival in patients with acute ischemic strokes: an institutional and institutional retrospective analysis”, researchers from the University of Wisconsin -Madison used data from patients from the university patients and a medical center of the university and a global health collaboration to see if patients with Ozempic experienced Strokes have not experienced Betteres outcomes who have not taken outcomes by outcomes by outsolas who are not patients who have not been to Strokes.
The global data set included 2,021,704 patients who had experienced stroke, 43,338 of which they were also in Ozempic, and the data set of the University of Wisconsin included 13,510 people who had experienced stroke, 190 of which Ozempic used. Death due to stroke was lower for Ozempic users in both cohorts. In the global data set, 5.26% of Ozempic users initially died from their stroke compared to 21.61% of non -users, and Ozempic users also had 77.5% chance of surviving their long -term stroke compared to 30.95% of non -work users. The university cohort showed similar results, with 5.26% of Ozempic users who die from stroke compared to 26.57% of patients who do not use Ozempic.
In the second study, also from the University of Wisconsin -Madison, “Association between the use of Ozempic and the risk of stroke: an analysis of the emergency department nationwide”, the researchers examined a large sample at the national level of records of the emergency department for people who experienced stroke and people who probably used Ozempic. They found associations between the potential Ozempic users and the probabilities of significantly reduced stroke. The research team suggests bringing this research beyond to evaluate the data directly from pharmacies to be even more precise about the relationship between Ozempic and the prevention of stroke.
The third study, “the impact of LPG-1 agonists on stroke, SAH and ICH: a multi-institutional multi-institutional cohort study,” was presented by researchers from the medical branch of the University of Texas in Galveston. They investigated whether LPG-1 inhibitors could improve the results of patients after cerebral hemorrhages (both spontaneous hemorrhages and those due to the rupture of cerebral aneurysm) and stroke. The equipment reviewed the records of the patients of 6 months and 12 months after each cerebral hemorrhage and 1 year and 2 years after each stroke, discovering that the use of the GLP-1 inhibitor was connected to a reduced risk of cognitive side effects, seizures, future cerebral hemorrhages and death after hemorrhage and cerebral stroke.
According to Ahmed Elbayomy, MD, researcher and data scientist in the Department of Neurological Surgery of the University of Wisconsin -Madison and main author of two of these studies, these results are very promising.
Certainly more research is needed, but seeing the possible protection offered by these medications is a fascinating finding. “
Ahmed Elbayomy, MD, Department of Neurological Surgery, University of Wisconsin – Madison
“This research could introduce a new perspective for the discussion about the prevention and mitigation of the devastating effects of the stroke and related brain injuries,” added Matias Costa, MD, of the Department of Neurosurgery of the Medical Branch of the University of Texas and author of the third study.
Fountain:
Neuro -interventional Surgery Society
(Tagstotransilate) Brain
